HC Wainwright reaffirmed their buy rating on shares of Inovio Pharmaceuticals (NASDAQ:INO) in a research report report published on Tuesday morning, TipRanks reports. They currently have a $13.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Roth Capital initiated coverage on Inovio Pharmaceuticals in a research report on Thursday, December 19th. They set a buy rating and a $13.00 target price for the company. Piper Jaffray Companies decreased their target price on Inovio Pharmaceuticals from $10.00 to $8.00 and set an overweight rating for the company in a research report on Thursday, January 2nd. Maxim Group restated a buy rating on shares of Inovio Pharmaceuticals in a research report on Thursday, January 23rd. Royal Bank of Canada restated a buy rating and set a $7.00 target price on shares of Inovio Pharmaceuticals in a research report on Thursday, January 23rd. Finally, Cantor Fitzgerald restated an overweight rating on shares of Inovio Pharmaceuticals in a research report on Monday, January 6th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Inovio Pharmaceuticals presently has an average rating of Buy and a consensus target price of $7.27.

Shares of Inovio Pharmaceuticals stock traded up $0.46 during trading on Tuesday, hitting $4.32. 27,896,162 shares of the company were exchanged, compared to its average volume of 8,579,615. The firm has a market capitalization of $352.74 million, a P/E ratio of -3.63 and a beta of 2.16. Inovio Pharmaceuticals has a 1-year low of $1.91 and a 1-year high of $5.95. The firm’s fifty day moving average price is $3.56 and its 200 day moving average price is $2.71. The company has a debt-to-equity ratio of 2.52, a current ratio of 5.06 and a quick ratio of 5.06.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.26) by $0.01. The company had revenue of $0.87 million during the quarter, compared to analyst estimates of $2.72 million. Inovio Pharmaceuticals had a negative return on equity of 179.91% and a negative net margin of 1,809.64%. During the same period in the previous year, the company earned ($0.27) EPS. As a group, equities research analysts anticipate that Inovio Pharmaceuticals will post -1.08 earnings per share for the current year.

In other Inovio Pharmaceuticals news, CEO Jong Joseph Kim acquired 22,500 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was acquired at an average cost of $3.11 per share, for a total transaction of $69,975.00. Following the transaction, the chief executive officer now owns 1,100,707 shares of the company’s stock, valued at $3,423,198.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.90% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of INO. ARK Investment Management LLC grew its position in shares of Inovio Pharmaceuticals by 8.6% in the 4th quarter. ARK Investment Management LLC now owns 4,584,966 shares of the biopharmaceutical company’s stock valued at $15,130,000 after purchasing an additional 362,276 shares during the period. BlackRock Inc. grew its position in shares of Inovio Pharmaceuticals by 4.5% in the 2nd quarter. BlackRock Inc. now owns 7,708,829 shares of the biopharmaceutical company’s stock valued at $22,665,000 after purchasing an additional 335,356 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Inovio Pharmaceuticals by 5.6% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,156,350 shares of the biopharmaceutical company’s stock valued at $10,571,000 after purchasing an additional 272,250 shares during the period. Nikko Asset Management Americas Inc. grew its position in shares of Inovio Pharmaceuticals by 5.6% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 5,156,350 shares of the biopharmaceutical company’s stock valued at $10,571,000 after purchasing an additional 272,250 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Inovio Pharmaceuticals by 166.5% in the 4th quarter. Renaissance Technologies LLC now owns 359,500 shares of the biopharmaceutical company’s stock valued at $1,186,000 after purchasing an additional 224,600 shares during the period. Institutional investors and hedge funds own 45.94% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.

Further Reading: How much money do you need to begin day trading?

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.